Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
Imeik Technology Development Co.,Ltd. (300896.SZ)
Beijing, CN
Imeik Technology Development Co.,Ltd. specializes in the research, development, manufacturing, and distribution of biomedical materials. The company's diverse product portfolio caters to both the medical aesthetics field and general skincare needs. Within its medical beauty offerings, Imeik provides a range of recognized brands including Moisten Angel, IFRESH, Yimei, Hearty, Bonita Bonita, and Tightly. Additionally, its comprehensive skincare line features hydrating lotions, anti-aging and firming serums, concentrated essence creams, revitalizing facial masks, restorative chitosan B5 sprays, and clarifying and illuminating liquids. Established in 2004, the company's operations are based in Beijing, China.
No mergers or acquisitions recorded for this company.
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| +5.16% | +1.56% | -8.95% | -26.64% | -27.94% | -26.09% | -38.38% | -67.60% | -78.33% | -22.38% | -22.38% |
Revenue flow
Revenue by geography
Revenue by segment
Revenue composition
By product
By geography
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
DCF figures are point estimates: small changes in growth or discount-rate assumptions move them materially. Read them as a reference, not a precise target.
| Rating | 2026-05 | Change |
|---|---|---|
| Strong Buy | 1 | 0 |
| Buy | 9 | -1 |
| Hold | 3 | -1 |
| Sell | 1 | 0 |
| Strong Sell | 0 | 0 |
-
Revenue growth Medical - Instruments & Supplies: +7.9%-19.9% Q1'26: -4.5% (vs Q1'25)
-
EPS growth Medical - Instruments & Supplies: +16.3%-34.2% Q1'26: -32.7% (vs Q1'25)
-
FCF margin FCF growth · Medical - Instruments & Supplies: +27.1%+48.6% Q1'26: +43.4% (vs Q1'25)
-
EBIT margin Medical - Instruments & Supplies: +13.5%+54.3% ★ Q1'26: +56.2% (vs Q1'25)
-
ROIC Medical - Instruments & Supplies: +6.0%+23.6% ★ Q1'26: +25.5% (vs Q1'25)
-
Share dilution Medical - Instruments & Supplies: +0.1%+0.1% Q1'26: -0.1% (vs Q1'25)
-
Debt / EBITDA Net debt/EBITDA · Medical - Instruments & Supplies: -0.24×0.01× ★ Q1'26: 0.18× (vs Q1'25)
* These projections are based on analyst consensus estimates and user-defined valuation multiples. This table is for informational purposes only and does not constitute a recommendation to buy or sell any security. Past performance is not indicative of future results.
| Metric |
Dec 2020 actual |
Dec 2021 actual |
Dec 2022 actual |
Dec 2023 actual |
Dec 2023 actual |
Dec 2024 actual |
Dec 2025 actual |
Dec 2026 11 Rev. Ana. 7 EPS Ana. |
Dec 2027 14 Rev. Ana. 9 EPS Ana. |
Dec 2028 10 Rev. Ana. 10 EPS Ana. |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue |
709.29M
est: 707.36M (+0.3%)
|
1.43B
est.
|
1.45B
est: 2.17B (-33.2%)
|
1.94B
est: 3.07B (-36.8%)
|
2.87B
est: 3.07B (-6.4%)
|
3.03B
est: 3.14B (-3.7%)
|
2.42B
est: 2.53B (-4.3%)
|
2.74B
2.61B – 2.92B
+8.4% YoY
|
3.10B
2.70B – 3.47B
+12.9% YoY
|
3.48B
3.43B – 3.54B
+12.4% YoY
|
| EBITDA |
513.70M
est: 502.44M (+2.2%)
|
1.02B
est.
|
1.13B
est: 1.54B (-26.3%)
|
1.51B
est: 2.25B (-33.0%)
|
2.19B
est: 2.25B (-2.6%)
|
2.31B
est: 2.30B (+0.5%)
|
1.39B
est: 1.85B (-25.0%)
|
2.01B
1.91B – 2.13B
+8.4% YoY
|
2.27B
1.98B – 2.54B
+12.9% YoY
|
2.55B
2.51B – 2.59B
+12.4% YoY
|
| EBIT |
502.72M
est: 495.42M (+1.5%)
|
1.00B
est.
|
1.12B
est: 1.52B (-26.0%)
|
1.49B
est: 2.21B (-32.4%)
|
2.16B
est: 2.21B (-2.1%)
|
2.28B
est: 2.26B (+1.0%)
|
1.32B
est: 1.82B (-27.7%)
|
1.97B
1.88B – 2.10B
+8.4% YoY
|
2.23B
1.94B – 2.50B
+12.9% YoY
|
2.50B
2.46B – 2.55B
+12.4% YoY
|
| Net Income |
439.75M
est: 421.21M (+4.4%)
|
927.67M
est.
|
957.98M
est: 1.39B (-31.3%)
|
1.26B
est: 2.02B (-37.3%)
|
1.86B
est: 2.02B (-7.8%)
|
1.96B
est: 2.10B (-6.6%)
|
1.29B
est: 1.51B (-14.6%)
|
1.37B
1.05B – 1.68B
-9.6% YoY
|
1.61B
1.17B – 1.89B
+17.4% YoY
|
1.83B
1.46B – 2.19B
+13.7% YoY
|
| SGA |
114.45M
est: 104.10M (+9.9%)
|
210.42M
est.
|
221.20M
est: 318.97M (-30.7%)
|
288.11M
est: 487.39M (-40.9%)
|
404.59M
est: 487.39M (-17.0%)
|
399.58M
est: 499.51M (-20.0%)
|
533.68M
est: 402.42M (+32.6%)
|
436.06M
415.08M – 463.40M
+8.4% YoY
|
492.36M
429.17M – 552.11M
+12.9% YoY
|
553.52M
544.45M – 562.59M
+12.4% YoY
|
| EPS |
1.79
est: 1.40 (+28.0%)
|
3.08
est.
|
3.16
est: 4.63 (-31.7%)
|
4.17
est: 6.68 (-37.6%)
|
6.15
est: 6.68 (-8.0%)
|
6.50
est: 6.94 (-6.3%)
|
4.28
est: 5.01 (-14.5%)
|
4.60
3.47 – 5.57
-8.1% YoY
|
5.19
3.89 – 6.28
+12.8% YoY
|
5.86
4.85 – 7.27
+12.9% YoY
|
| Date | Rating | Overall | DCF | ROE | ROA | D/E | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
| 2026-05-29 | A- | 4/5 | 5/5 | 4/5 | 5/5 | 3/5 | 1/5 | 2/5 |
| 2026-05-28 | A- | 4/5 | 5/5 | 4/5 | 5/5 | 3/5 | 1/5 | 2/5 |
| 2026-05-27 | A- | 4/5 | 5/5 | 4/5 | 5/5 | 3/5 | 1/5 | 2/5 |
| 2026-05-26 | A- | 4/5 | 5/5 | 4/5 | 5/5 | 3/5 | 1/5 | 2/5 |
| 2026-05-25 | A- | 4/5 | 5/5 | 4/5 | 5/5 | 3/5 | 1/5 | 2/5 |
| 2026-05-22 | A- | 4/5 | 5/5 | 4/5 | 5/5 | 3/5 | 1/5 | 2/5 |
| 2026-05-21 | A- | 4/5 | 5/5 | 4/5 | 5/5 | 3/5 | 1/5 | 2/5 |
| 2026-05-20 | A- | 4/5 | 5/5 | 4/5 | 5/5 | 3/5 | 1/5 | 2/5 |
| 2026-05-19 | A- | 4/5 | 5/5 | 4/5 | 5/5 | 3/5 | 1/5 | 2/5 |
| 2026-05-18 | A- | 4/5 | 5/5 | 4/5 | 5/5 | 3/5 | 1/5 | 2/5 |
| 2026-05-15 | A- | 4/5 | 4/5 | 4/5 | 5/5 | 3/5 | 2/5 | 2/5 |
| 2026-05-14 | A- | 4/5 | 4/5 | 4/5 | 5/5 | 3/5 | 2/5 | 2/5 |
| 2026-05-13 | A- | 4/5 | 4/5 | 4/5 | 5/5 | 3/5 | 2/5 | 2/5 |
| 2026-05-12 | A- | 4/5 | 4/5 | 4/5 | 5/5 | 3/5 | 2/5 | 2/5 |
| 2026-05-11 | A- | 4/5 | 4/5 | 4/5 | 5/5 | 3/5 | 2/5 | 2/5 |
| 2026-05-08 | A- | 4/5 | 4/5 | 4/5 | 5/5 | 3/5 | 2/5 | 2/5 |
| 2026-05-07 | A- | 4/5 | 4/5 | 4/5 | 5/5 | 3/5 | 2/5 | 2/5 |
| 2026-05-06 | A- | 4/5 | 4/5 | 4/5 | 5/5 | 3/5 | 2/5 | 2/5 |
| 2026-04-30 | A- | 4/5 | 4/5 | 4/5 | 5/5 | 3/5 | 2/5 | 2/5 |
| 2026-04-29 | A- | 4/5 | 4/5 | 4/5 | 5/5 | 3/5 | 2/5 | 2/5 |
| 2026-04-28 | A- | 4/5 | 4/5 | 4/5 | 5/5 | 3/5 | 2/5 | 2/5 |
| 2026-04-27 | B+ | 3/5 | 4/5 | 4/5 | 5/5 | 2/5 | 2/5 | 2/5 |
| 2026-04-24 | B+ | 3/5 | 4/5 | 4/5 | 5/5 | 2/5 | 2/5 | 2/5 |
| 2026-04-23 | B+ | 3/5 | 4/5 | 4/5 | 5/5 | 2/5 | 2/5 | 2/5 |
| 2026-04-22 | A- | 4/5 | 4/5 | 4/5 | 5/5 | 3/5 | 2/5 | 2/5 |
| 2026-04-21 | B+ | 3/5 | 4/5 | 4/5 | 5/5 | 2/5 | 2/5 | 2/5 |
| 2026-04-20 | B+ | 3/5 | 4/5 | 4/5 | 5/5 | 2/5 | 2/5 | 2/5 |
| 2026-04-17 | B+ | 3/5 | 4/5 | 4/5 | 5/5 | 2/5 | 2/5 | 2/5 |
| 2026-04-16 | B+ | 3/5 | 4/5 | 4/5 | 5/5 | 2/5 | 2/5 | 2/5 |
Owner Earnings
Ownership Overview
Ownership breakdown not available.
No beneficial ownership filings recorded.
Institutional Activity (13F)
Institutional history not available.
Top holders not available.
ETF Ownership
| # | ETF | Weight | Est. AUM exposure | TER |
|---|---|---|---|---|
| 1 | KraneShares MSCI All China Health Care Index ETF KURE | 0.68% | 539.6K | 0.79% |
| 2 | VanEck ChiNext ETF CNXT | 0.18% | 216.9K | 0.65% |
| 3 | HSBC MSCI China A UCITS ETF HMCT.L | 0.14% | 185.7K | 0.30% |
| 4 | iShares MSCI China A ETF CNYA | 0.07% | 167.2K | 0.60% |
| 5 | Samsung KODEX China CSI300 ETF 283580.KS | 0.06% | 128.8K | 0.12% |
| 6 | Amundi MSCI China A UCITS ETF Acc CNAA.L | 0.06% | 84.6K | 0.35% |
| 7 | iShares MSCI China A UCITS ETF CNYA.L | 0.05% | 1.60M | 0.40% |
| 8 | iShares MSCI China A UCITS ETF CNYE.MI | 0.05% | 52.8K | 0.45% |
| 9 | Xtrackers Harvest CSI300 UCITS ETF 1D ASHR.L | 0.05% | 160.3K | 0.65% |
| 10 | Xtrackers MSCI China A UCITS ETF 1C XX2D.L | 0.05% | 68.4K | 0.35% |
Insider Activity
No insider activity available.
Insider history not available.
No recent insider transactions.
Executive team
Executive compensation
Executive compensation not available.
No CEO compensation history available.
Proxy statements
No proxy statements available for this company yet.
Recent SEC filings
No SEC filings available for this company yet.
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Liu Dan | Accounting Supervisor | — | — |
| Renchao Zhang | Chief Financial Officer | — | male |
| Yifeng Shi | GM & Director | — | male |
No data available for this company.
No Senate trading activity found for this company.
No House trading activity found for this company.
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for 300896.SZ
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
